GlassScriptPhysician profile
Richard Silva
NPI 1366497588
$1,092.90
in general payments reported to CMS, 2019-2025
10 companies · $49.52 in 2025
The $49.52 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.36 · 2021: $152 · 2022: $236 · 2023: $107 · 2024: $529 · 2025: $49.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.01 |
| Education | $157.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $540.67 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $157.49 | 2024 | |
| Lilly USA, LLC | $128.90 | 2021-2025 | Zepbound, Mounjaro |
| Altathera Pharmaceuticals LLC | $125.67 | 2024 | Sotalol Hydrochloride |
| Insulet Corporation | $42.81 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $33.73 | 2025 | Fruzaqla |
| Pfizer INC. | $26.93 | 2024 | |
| Dermira, INC. | $19.36 | 2020 | |
| Lucid Diagnostics INC. | $17.34 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.